Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy.
The present study was designed to test if the serum cytokines (interleukin, or IL-1beta, -2, -2r, -6, -6r, -8, and -10, and tumor necrosis factor alpha, or TNF-alpha) and osteocalcin levels were different between 50 osteoporotic and 30 postmenopausal nonosteoporotic women and to evaluate the efficacy of calcitonin therapy during 6 months on serum cytokines and osteocalcin levels in postmenopausal osteoporotic women. In our study, serum levels of osteocalcin, TNF-alpha, IL-2, and IL-8 were significantly higher in the patient group (P < 0.05), whereas serum levels of IL-10 and IL-6r were significantly lower in the patient group (P < 0.05). When analysed separately according to bone turnover, serum levels of IL-10 and IL-6r were significantly lower in the normal-turnover group (P < 0.05), and IL-2, IL-8, and TNF-alpha were significantly higher in the high-turnover group than in the control group (P < 0.05). Statistically significant improvement seemed to happen in the patients receiving calcitonin plus calcium therapy (P < 0.05) concerning levels of serum IL-6r at the 1st month (P < 0.05), IL-10, IL-2r, IL-6r, and osteocalcin at the 3rd month, and IL-6r and osteocalcin at the end of the 6th month. Our findings demonstrate that calcitonin plus calcium therapy appears to be particularly more effective for patients with high turnover. In addition, our study suggests that IL-10 and IL-6r may have an important role in normal-turnover osteoporosis, while IL-2, IL-8, and TNF-alpha may play an important role in high-turnover postmenopausal osteoporosis.
Gür
Ali
A
Department of Physical Medicine and Rehabilitation, Dicle University School of Medicine, Diyarbakir, Turkey. alig@dicle.edu.tr
Denli
Aziz
A
Nas
Kemal
K
Cevik
Remzi
R
Karakoc
Mehmet
M
Sarac
Aysegul Jale
AJ
Erdogan
Ferda
F
D015502:Absorptiometry, Photon; D000368:Aged; D000704:Analysis of Variance; D015415:Biomarkers / Q000032:analysis; D015519:Bone Density / Q000502:physiology; D002116:Calcitonin / Q000008:administration & dosage*; D017610:Calcium Compounds / Q000008:administration & dosage*; D016022:Case-Control Studies; D016207:Cytokines / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D007273:Injections, Intramuscular; D007378:Interleukins / Q000032:analysis; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000503:physiopathology*; D011336:Probability; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
D015415:Biomarkers; D017610:Calcium Compounds; D016207:Cytokines; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D002116:Calcitonin